# A Single Dose Study of MK-8266 (MK-8266-001)

> **NCT01025791** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 25 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** MK-8266 0.1 mg
- **DRUG:** MK-8266 1.0 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01025791
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-18
- **Primary completion:** 2010-05-14
- **Final completion:** 2010-05-14
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01025791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01025791, "A Single Dose Study of MK-8266 (MK-8266-001)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01025791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*